Business Context and Reporting Period
This Form 8-K, dated October 20, 2020, reports that Panacea Acquisition Corp. (a Delaware special purpose acquisition company) has entered into a definitive Merger Agreement with Nuvation Bio Inc. The transaction involves a merger where Nuvation will become a wholly-owned subsidiary of Panacea, effectively taking Nuvation public. The filing details the terms of the merger, related financing agreements, and conditions precedent to closing.
Key Financial Metrics and Transaction Terms
- Transaction Structure: Nuvation shareholders will receive Panacea Class A common stock based on an Exchange Ratio calculated as 150,000,000 divided by Nuvation's fully diluted company shares.
- PIPE Investment: Private Investment in Public Equity (PIPE) investors have subscribed for 47,755,000 shares of Panacea Class A common stock at an aggregate purchase price of $477,550,000.
- Forward Purchase Agreement: Includes $25,000,000 in proceeds from a forward purchase agreement entered into during Panacea's IPO.
- Total Equity Financing: The combination of the PIPE Investment and the forward purchase agreement totals slightly more than $500,000,000.
- Cash Closing Requirement: The merger requires at least $500.0 million in cash available at closing (Trust Account balance + Forward Purchase + PIPE), subject to a reduction if the Founder does not fund at least $20.0 million of the PIPE.
- Net Tangible Assets: Panacea must have at least $5,000,001 of net tangible assets immediately after the effective time.
- Warrant Exercise Price: Redeemable warrants are exercisable for one share of Class A common stock at $11.50 per share.
Material Changes and Conditions
The filing represents a material change in corporate structure for both entities. Key conditions to closing include:
- Approval by stockholders of both Panacea and Nuvation.
- Effectiveness of the registration statement on Form S-4.
- Expiration of the Hart-Scott-Rodino Antitrust waiting period.
- Listing approval on the New York Stock Exchange.
- Nuvation must consummate an internal recapitalization.
- Termination rights exist if the closing does not occur by April 18, 2021.
Guidance, Outlook, and Risks
Management Commentary and Outlook: The filing contains forward-looking statements regarding the anticipated cash available, the use of proceeds, and the progress of Nuvation's development programs. Management expects the transaction to provide capital for Nuvation's growth and commercialization efforts.
Risks and Contingencies:
- Redemption Risk: The cash available at closing is contingent on the number of Panacea stockholders who exercise their right to redeem shares.
- Regulatory and Clinical Risk: Risks include failure of product candidates to progress through clinical development, obtain regulatory approval, or achieve market acceptance.
- Operational Risk: Dependence on third parties for manufacturing and clinical services, and potential impacts from the COVID-19 pandemic.
- Transaction Risk: Failure to obtain necessary stockholder or regulatory approvals could result in termination of the merger.
Lock-Up Agreements: The Sponsor and Founder are subject to a 365-day lock-up, while certain Nuvation stockholders are subject to an 180-day lock-up, unless the stock price exceeds $12.00 per share for 20 trading days within a 30-day period (commencing 150 days post-closing).
Investor Verification Checklist
- Verify the final number of shares redeemed by Panacea public stockholders, as this directly impacts the cash available at closing and the Exchange Ratio.
- Confirm the final amount funded by the Founder into the PIPE Investment to ensure the $500 million cash closing requirement is met.
- Review the upcoming Form S-4 registration statement for detailed financial data on Nuvation and the final terms of the merger.
- Monitor the status of the Hart-Scott-Rodino waiting period and NYSE listing approval.
- Assess the clinical development timelines and regulatory pathways for Nuvation's product candidates as disclosed in the investor presentation (Exhibit 99.2).